Evaluation of the Components of the Insulin-like Growth Factors System in GH-deficient Adults: Effects of Twelve-month rhGH Treatment

The impact of GH deficiency and rhGH replacement therapy on IGF-I, IGFBP-3 and ALS levels has been widely studied. There is less information available on IGF-II levels, the component of the ternary complex poorly dependent on GH. We investigate the components of IGFs system in 36 GHD adults (28M, 8F, age 45 +/- 14 yrs) before and after 12 months of rhGH therapy (mean dose 0.3 +/- 0.1 mg/day). One-hundred healthy sex- and age-matched subjects were studied for comparison. At baseline, GHD patients showed IGF-I and IGF-II levels and IGFs to IGFBP-3 molar ratios that were lower than controls. During therapy, IGF-I levels increased (p < 0.01) to normal range. IGF-II levels, though higher than at baseline (p < 0.01), remained lower than in controls (p < 0.01). ALS and IGFBP-3 significantly increased (p < 0.001). These modifications resulted in normalization in IGF-I to IGFBP-3 ratio, while no change in IGF-II to IGFBP-3 ratio was observed. In conclusion, the increase of serum IGF-II levels during rhGH treatment in GHD patients probably reflects the increase in the other components of ternary complex (ALS and IGFBP-3). However, serum IGF-II levels as well as IGF-II to IGFBP-3 ratio, although increased, were definitely lower than in controls. This last result, given the increasing evidences of a direct implication of IGF-II in cancer, may further confirm the safety of rhGH replacement in adults with severe GHD as diagnosed by appropriate stimulation tests.

[1]  S. Bustin,et al.  Evidence for a link between IGF-I and cancer. , 2004, European journal of endocrinology.

[2]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[3]  J. Witte,et al.  Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States) , 2003, Cancer Causes & Control.

[4]  C. Ronchi,et al.  Growth Hormone Therapy in GH-deficient Adults: Continuous vs. Alternate-days Treatment , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[5]  C. Roberts,et al.  The insulin-like growth factor system and cancer. , 2003, Cancer letters.

[6]  S. Nussey,et al.  Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults. , 2002, The Journal of clinical endocrinology and metabolism.

[7]  R. Baxter.  Inhibition of the Insulin-Like Growth Factor (IGF)–IGF-Binding Protein Interaction , 2001, Hormone Research in Paediatrics.

[8]  S. Mohan,et al.  Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. , 2000, The Journal of clinical endocrinology and metabolism.

[9]  Clayton,et al.  Monitoring serum insulin‐like growth factor‐I (IGF‐I), IGF binding protein‐3 (IGFBP‐3), IGF‐I/IGFBP‐3 molar ratio and leptin during growth hormone treatment for disordered growth , 2000, Clinical endocrinology.

[10]  I. McCutcheon,et al.  The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. , 2000, Endocrine reviews.

[11]  Y Schutz,et al.  Reference values of fat-free and fat masses by bioelectrical impedance analysis in 3393 healthy subjects. , 2000, Nutrition.

[12]  P. Clayton,et al.  Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout life. , 1999, The Journal of clinical endocrinology and metabolism.

[13]  C. Mantzoros,et al.  IGF‐I and IGF‐II in relation to colorectal cancer , 1999, International journal of cancer.

[14]  N. Skakkebaek,et al.  The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency. , 1998, The Journal of clinical endocrinology and metabolism.

[15]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[16]  A. Shimatsu,et al.  Serum Insulin-like growth factor-II (IGF-II) levels in patients with acromegaly and growth hormone deficiency: correlation with IGF-I and IGF binding protein-3. , 1996, Endocrine journal.

[17]  J. Toretsky,et al.  Involvement of IGF-II in human cancer. , 1996, The Journal of endocrinology.

[18]  R. Baxter,et al.  Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. , 1996, The Journal of clinical endocrinology and metabolism.

[19]  E. Arvat,et al.  New approach to the diagnosis of growth hormone deficiency in adults. , 1996, European journal of endocrinology.

[20]  P. Rotwein,et al.  Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. , 1989, Endocrine reviews.

[21]  A. Juul,et al.  Insulin‐like growth factors (IGF‐I, free IGF‐I, and IGF‐II) and insulin‐like growth factor binding proteins (IGFBP‐2, IGFBP‐3, IGFBP‐6, and ALS) in blood circulation , 1999, Journal of clinical laboratory analysis.

[22]  Stampfer,et al.  Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. , 1999, Journal of the National Cancer Institute.

[23]  F. Minuto,et al.  Functions and regulation of the acid-labile subunit of the 150 K complex. , 1995, Progress in growth factor research.

[24]  J A Hodgdon,et al.  Lean body mass estimation by bioelectrical impedance analysis: a four-site cross-validation study. , 1988, The American journal of clinical nutrition.